Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lower mean weight after 14 days intravenous administration peptide YY3–36 (PYY3–36) in rabbits

International Journal of Obesity volume 30, pages 68–72 (2006)Cite this article

Abstract

Objective:

Endogenous peptide YY3–36 (PYY3–36) is associated with postprandial regulation of appetite. We investigated the safety and effectiveness of peripherally administered synthetic human PYY3–36 for 14 days in New Zealand white rabbits. Weight gain and food consumption were assessed and pharmacokinetics and toxicity characterized.

Research methods and procedures:

In all, 24 animals were randomized to one of four intravenous treatment groups – control (0.9% saline) or PYY3–36 bolus at 4.1, 41.0, or 205 μg/kg/day. Body weight and consumption of fixed food allotment were measured daily. Hematology and serum chemistries were profiled at baseline and Day 15, and pharmacokinetics measured following dose 14. Histopathologic examination of designated tissues and organs in control and PYY3–36 205 μg/kg animals was conducted. All animals were subject to clinical and macroscopic observation.

Results:

The trend effect of higher dose PYY3–36 on lower average weight was significant (P=0.01; Day 14 compared to baseline) and its effect on reduced food consumption was suggested (P=0.065; number of days ⩽75% food eaten, compared with control). Hematology and clinical chemistries were within normal limits pretest and at Day 15. No clinical, macroscopic, histologic, or microscopic changes related to the test article were observed over the course of study.

Discussion:

Lower average weight occurs in rabbits treated once daily with intravenous injection PYY3–36 (205 μg/kg/day) over 14 days. No clinical or histologic signs of toxicity were observed. Further research is warranted to describe alternate routes of peripheral administration for optimizing weight control.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Eberlein GA, Eysselein VE, Schaeffer M, Layer P, Grandt D, Goebell H et al. A new molecular form of PYY: structural characterization of human PYY(3–36) and PYY(1–36). Peptides 1989; 10: 797–803.

    Article  CAS  Google Scholar 

  2. Keire DA, Mannon P, Kobayashi M, Walsh JH, Solomon TE, Reeve JR . Primary structures of PYY, [Pro34] PYY and PYY (3–36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 2000; 279: G126–G131.

    Article  CAS  Google Scholar 

  3. Pedersen-Bjergaard U, Hoest U, Kelbaek H, Schifter S, Rehfeld JH, Faber J et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest 1996; 56: 497–503.

    Article  CAS  Google Scholar 

  4. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR . Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070–1077.

    Article  CAS  Google Scholar 

  5. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL et al. Leptin activates the anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411: 480–484.

    Article  CAS  Google Scholar 

  6. Batterham RL, Bloom SR . The gut hormone peptide YY regulates appetite. Ann NY Acad Sci 2003; 944: 162–168.

    Article  Google Scholar 

  7. Grandt D, Schimiczek M, Beglinger Ch, Layer P, Goebell H, Eysselein VE et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY1–36 and PYY3–36 . Regul Peptides 1994; 51: 151–159.

    Article  CAS  Google Scholar 

  8. Grandt D, Teyssen S, Schimiczek M, Reeve JR, Feth F, Rascher W et al. Novel generation of hormone receptor specificity by amino terminal processing of peptide YY. Biochem Biophys Res Comm 1992; 186: 1299–1306.

    Article  CAS  Google Scholar 

  9. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG . Central nervous system control of food intake. Nature 2000; 404: 661–671.

    Article  CAS  Google Scholar 

  10. Sheikh SP . Neuropeptide Y and peptide YY: major modulators of gastrointestinal blood flow and function. Am J Physiol 1991; 261: G701–G715.

    CAS  PubMed  Google Scholar 

  11. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen M, Dakin C et al. Gut hormone PYY3–36 physiologically inhibits food intake. Nature 2002; 418: 650–654.

    Article  CAS  Google Scholar 

  12. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY 3–36. N Engl J Med 2003; 349: 941–948.

    Article  CAS  Google Scholar 

  13. Institute of Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press, 1996.

  14. Cook RD . Detection of influential observations in linear regression. Technometrics 1997; 19: 15–18.

    Google Scholar 

  15. Draper NR, Smith N . Applied Regression Analysis, 3rd edn, Section 8.3. New York: John Wiley and Sons Inc., 1998.

    Book  Google Scholar 

  16. Tekeli S . Occurrence of hair-fragment emboli in the pulmonary vascular system of rats. Vet Pathol 1974; 11: 482–485.

    Article  CAS  Google Scholar 

  17. Halatchev IG, Ellacott KLJ, Fan W, Cone RD . PYY3–36 inhibits food intake through a melanocortin-4 receptor-independent mechanism. Endocrinology 2004; 145: 2585–2590.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nastech Pharmaceutical Company Inc., Bothell, WA, USA

    A P Sileno, G C Brandt, B M Spann & S C Quay

Authors
  1. A P Sileno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G C Brandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B M Spann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S C Quay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B M Spann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sileno, A., Brandt, G., Spann, B. et al. Lower mean weight after 14 days intravenous administration peptide YY3–36 (PYY3–36) in rabbits. Int J Obes 30, 68–72 (2006). https://doi.org/10.1038/sj.ijo.0803067

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803067

Keywords

This article is cited by

Search

Advanced search

Quick links